Rahlfs Capital LLC Acquires New Position in Johnson & Johnson (NYSE:JNJ)

Rahlfs Capital LLC bought a new position in Johnson & Johnson (NYSE:JNJ) during the 4th quarter, HoldingsChannel reports. The fund bought 10,111 shares of the company’s stock, valued at approximately $1,462,000. Johnson & Johnson makes up approximately 1.4% of Rahlfs Capital LLC’s portfolio, making the stock its 20th largest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Principal Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 10.5% during the third quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock valued at $562,723,000 after purchasing an additional 329,473 shares in the last quarter. United Bank lifted its stake in Johnson & Johnson by 5.6% during the 3rd quarter. United Bank now owns 3,788 shares of the company’s stock valued at $614,000 after acquiring an additional 202 shares during the period. Texas Capital Bank Wealth Management Services Inc boosted its holdings in shares of Johnson & Johnson by 24.6% during the 3rd quarter. Texas Capital Bank Wealth Management Services Inc now owns 6,224 shares of the company’s stock valued at $1,009,000 after acquiring an additional 1,227 shares during the last quarter. Wahed Invest LLC boosted its holdings in Johnson & Johnson by 7.7% in the third quarter. Wahed Invest LLC now owns 58,301 shares of the company’s stock worth $9,448,000 after purchasing an additional 4,158 shares during the last quarter. Finally, Voya Financial Advisors Inc. raised its stake in Johnson & Johnson by 3.3% during the 3rd quarter. Voya Financial Advisors Inc. now owns 4,716 shares of the company’s stock valued at $761,000 after buying an additional 149 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 4.3 %

Shares of NYSE:JNJ opened at $153.03 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The firm has a market capitalization of $368.77 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The business has a 50 day simple moving average of $159.75 and a two-hundred day simple moving average of $155.91.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $2.29 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on JNJ shares. Guggenheim reissued a “neutral” rating on shares of Johnson & Johnson in a report on Wednesday. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday. Barclays boosted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Raymond James dropped their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Finally, Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $171.33.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.